Skip to content

“I suddenly noticed blurry vision in one eye, and it got much worse over the course of a couple days. My doctor diagnosed me with a retinal vein occlusion and said I can lose my vision permanently without frequent treatment.”


The retina needs a constant supply of oxygen and nutrients delivered by blood vessels. In retinal vein occlusion (RVO), a blockage occurs in either the central retinal vein (CRVO) or a branch retinal vein (BRVO). As a result of the RVO, ischemia develops within the retina and VEGF levels are elevated. Patients with RVO are at risk for developing: 

  • Macular edema: Fluid leakage into the center of the retina causing decreased vision.
  • Retinal and Anterior Segment Neovascularization: Abnormal, blood vessels grow in response to ischemia and excess VEGF. Neovascularization easily bleeds and may lead to severe vision loss and neovascular glaucoma.


Our therapeutic candidate tarcocimab tedromer, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, tarcocimab tedromer may relieve the high treatment burden for patients, their family members, and physicians. 

Tarcocimab tedromer is being developed towards a once every two months or longer treatment regimen.